{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-274670","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2021-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.642550+00:00","generated_at":"2026-06-29T03:20:52.065827+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Repligen to acquire Avitide for ~$150M in cash and stock, adding affinity chromatography capabilities","bullets":["Total consideration ~$150M, consisting of $75M cash and $75M in Repligen common stock, plus three-year earnout.","Avitide expected to contribute ~$10M revenue in 2022 and be accretive to adjusted EPS in 2023.","Transaction strengthens Repligen's affinity ligand discovery platform for gene therapy and other modalities.","Deal expected to close in Q3 2021; funded with cash on hand ($734M at June 30, 2021)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-274670","json":"https://secwatch.observer/filing/0001193125-21-274670.json","markdown":"https://secwatch.observer/filing/0001193125-21-274670.md","text":"https://secwatch.observer/filing/0001193125-21-274670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000119312521274670/0001193125-21-274670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000119312521274670/d217967d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T03:20:52.065827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}